# Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event

> **NCT00347217** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3840 (estimated)

## Conditions studied

- Hypercholesteremia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00347217
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2009-01
- **Target enrollment:** 3840 (ESTIMATED)
- **Last updated:** 2011-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00347217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00347217, "Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00347217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*